Jobs
Interviews

Bioxera Pharma

BioXera Pharma specializes in the development of innovative processes for a wide range of products. The business comprises of manufacturing and sales of APIs and intermediates in both domestic and international markets, including the regulated markets. With a strong R&D backbone, word class infrastructure, headed by a team of technocrats, BioXera has established a large portfolio of molecules in commercial production along with several more in the pipeline. Today, BioXera Pharma operates a state-of- the art API manufacturing facility at Ambernath, Maharashtra spread over a plot area of 110,000 sq.ft. With the ability to handle complex chemical synthesis, BioXera has built up strength in the development, process optimisation and cGMP production of APIs and intermediates. Currently, we export API and intermediates to over 27 countries, and are poised to enter more shortly.

12 Photos in Bioxera Pharma
Ac9h4nq2j1j Pqvo7xfudb3yj Kfxtrius8xo5iempifwdrojss Legfbmguegyhedjhs9624wgh8ybswg 6b2niizzq4amoewl7hvmwn2mboeldhk6y4wmp0kjh8wj0ylugxowkjiho4g=s387 K No
Ac9h4nruo9 Patsho6kwoum81g3mr5oda9gmpt6n9tzshdlybbc Lzsgujlonkzadhecfpwu5v0civp 1enf006rxzc1y5kvvlth4ltqsjm3jfrcd Bcfa6wapdixgw8hbhtyguhx23f W=s450 K No
Ac9h4nrcombxx4hbt9a Fbwx55fbwbosvjolvp7oeb7mpgmj8nhnyg287pfyrsu37kbi3fpbjzw07ggb1oelxky4wuahdiuh1rumtayvdd6m Ne9a4gfluqnkbboani7ifjteiwhz7k6hw=s677 K No
Ac9h4noiynp2fieb7nmaoi4ecszoguedcecbosgk6nryapfhzf0myupo1q3hydlxpgqvbczos661vyoqk8nexlvajvuavmbgszhd2qmdrd T5q3bnlr9vb8 0ql Ipqjv32620jojbmlwq=s677 K No
Ac9h4nq4f2cfqwx7nmh0acik9 T7evrnng Xurg9lxxbawrkrhfniiwlckivau23hjdjhia6zpp Ort9o5z4gdy9rrq2otnsnlfliodnowlrba 6kkrylnk A1kusbgatfrpjhfs87ru=s451 K No
Ac9h4nqq6uvjqp81tfd0 Sbg75qsnnmbrhw7cx3qtqql Uzpows3bsat1ydv01otsmu7piqgzf4ir2 Ff2dxye31dioy5nnmm5l48hlnzb4nr4rnw6p Yfetqj Higbof1jvj9h0wwib=s387 K No
Ac9h4no1dzihd71bo1ohd4wyzeiz6pdmpcjbz Oevrmh Duaxodnlmclivcjpurzbbq8gytc5k Gatjbbs52nj8rn1vs7adaswvmvlfqpazmuyygrotvut5k5d4po8g7y7veeuwi0h4=s508 K No
Ac9h4nqvdhsogw1ljcthk1f5ffdoco6xx60fow2lrstacxkfh7tu4dsqeidr  3 Gvoggcoaq5xn Zefp98yptytfkdrxnfdohzlgslrgy77lisjkgkx3oaazwbb1dcqluz69wufejxyfg=s451 K No
Ac9h4nptpuinw48l1ys8gyjzkm Ezicd  J3le4dmwmxyxx Jrk9uvuavvkgy44zxvukkztx5dn7mcolzb5o 8odnfrqtsbflykqh Nqxag5wnz B7r2gbwiw3agnfqgljavm44a 1es=s387 K No
Ac9h4nroixk9vjer6drujftyy5eqpvexxbebwbjsjsligj3jidvvxwgalxmpdh 8g91 2cddmsts Pqvzrqmvshjnjknhu8apjm42naqlfqfab5qemgwyztb71ssybwxp605dt4hdehl=s406 K No
Ac9h4nrzkwdc41gpzj1to2covdbkjnuh9dl4vtpdruq1wttkj25mpwfelhfwgslwjpbei9x9vgrachwtr Zsl8hvvoakerdgib2ygp9exnoltwar3lvthvm Ivkbou Hkgnxnplp0lq3=s677 K No
Ac9h4nrl7 F0mlkg7z8 Pwoxu M9jnsvbcvbm2a491edtxqknpmnpizichpbhx3qmijaswsxx5p7bu0nm1kw1cinn4yd098cbgatckqnn51cb5dkjbuslxgcesliya 2r9c0xiggueu=s677 K No